Moderna swings to profit as momentum for cancer vaccine builds
Moderna swung to a profit and raised its 2026 financial outlook, driven by strong international demand for its COVID-19 vaccine and growing momentum for its pipeline products. The company's chief executive officer stated that newer vaccines are gaining traction as the biotech firm looks to future growth from new products, including a flu vaccine and a personalized cancer treatment. Following the quarterly earnings report that beat forecasts, company shares jumped 10 percent.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Moderna swung to a profit and raised its annual revenue forecast.
- ✓ The company's chief executive officer stated that newer vaccines are gaining traction.
- ✓ Moderna shares jumped 10 percent after third-quarter earnings beat forecasts.
- ✓ The biotech company reported a profit while looking to future growth with new products including a flu vaccine and a personalized cancer treatment.
What changed
Moderna raised its annual revenue forecast and posted a quarterly profit, fueled by overseas demand for its COVID-19 shot and progress in its cancer vaccine.
Live updates
-
Moderna Swings to Profit as Cancer Vaccine Momentum Builds
Moderna swung to a profit and raised its 2026 financial outlook, driven by strong international demand for its COVID-19 vaccine and growing momentum for its pipeline products. The company's chief executive officer stated that newer vaccines are gaining traction as the biotech firm looks to future growth from new products, including a flu vaccine and a personalized cancer treatment. Following the quarterly earnings report that beat forecasts, company shares jumped 10 percent.
Why it matters
The financial turnaround highlights stabilization in the market for COVID-19 immunizations alongside broader commercial adoption of newer pipeline treatments. Moderna is positioning itself for future growth by expanding beyond its core pandemic products into oncology and influenza vaccines. These developments mark a turning point for the biotech company as it seeks sustained profitability.
What is confirmed
- Moderna swung to a profit and raised its annual revenue forecast.
- The company's chief executive officer stated that newer vaccines are gaining traction.
- Moderna shares jumped 10 percent after third-quarter earnings beat forecasts.
- The biotech company reported a profit while looking to future growth with new products including a flu vaccine and a personalized cancer treatment.
What to watch next
- Commercial progress and regulatory updates on Moderna's personalized cancer treatment and flu vaccine
- International sales figures for the COVID-19 vaccine in subsequent quarters
confidence 100%Sources used for this update (9)
- finance.yahoo.com — Yahoo Finance - Stock Market Live, Quotes, Business & Finance News
- consent.yahoo.com — Latest news and current events updates | Yahoo News Singapore
- CNBC — Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Financial Times — Moderna swings to profit as momentum for cancer vaccine builds
- Reuters — Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas
- WSJ — Moderna Swings to Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes
- Yahoo Finance — Moderna Shares Jump 10% as Q3 Earnings Beat Forecasts and Revenue Outlook Improves
- pharma.economictimes.indiatimes.com — Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas
- malaysia.news.yahoo.com — Canada's Enbridge posts higher quarterly profit - Yahoo News Malaysia
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community